Top

Published in:

01-04-2013 | Editorial

Off-label, but on-target: Use of regadenoson with exercise

Authors: Robert C. Hendel, MD, Lauren Frost, MD

Published in: Journal of Nuclear Cardiology | Issue 2/2013

Excerpt

Pharmacologic stress testing has evolved considerably during the past 25 years, providing an extension of the benefits of physiologic imaging to those who are unable to undergo maximal exercise testing. Vasodilator stress myocardial perfusion imaging now compromises more than half of nuclear cardiology procedures in the United States,1 as multiple procedural advances and additional clinical evidence support this procedure as a mainstay in cardiac testing. …

Iskandrian AE. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: Results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol 2007;14:645-58.PubMedCrossRef

Holly TA, Satran A, Bromet DS, et al. The impact of adjunctive adenosine infusion during exercise myocardial perfusion imaging: Results of the both exercise and adenosine stress test (BEAST) trial. J Nucl Cardiol 2003;10:291-6.PubMedCrossRef

Elliott MD, Holly TA, Leonard SM, Hendel RC. Impact of an abbreviated adenosine protocol incorporating adjunctive treadmill exercise on adverse effects and image quality in patients undergoing stress myocardial perfusion imaging. J Nucl Cardiol 2000;7:584-9.PubMedCrossRef

Jamil G, Ahlberg AQ, Eliott MD, et al. Impact of limited treadmill exercise on adenosine Tc-99m sestambi single-photon emission computed tomographic myocardial perfusion imaging in coronary artery disease. Am J Cardiol 1999;84:400-3.PubMedCrossRef

Thomas GS, Prill NV, Majmundar H, et al. Treadmill exercise during adenosine infusion is safe, results in fewer adverse reactions and improves myocardial perfusion imaging. J Nucl Cardiol 2000;7:439-46.PubMedCrossRef

Vitola JV, Brambatti JC, Caligaris F, et al. Exercise supplementation to dipyridamole prevents hypotension, improves electrocardiogram sensitivity, and increases heart-to-liver activity ratio on Tc-99m sestamibi imaging. J Nucl Cardiol 2001;8:652-9.PubMedCrossRef

Thomas GS, Thompson RC, Miyamato MI, et al. The regEx trial: A randomized, double-blind, placebo- and active-controlled pilot study combining regadenoson, a selective A(2A) adenosine agonist, with low-level exercise, in patients undergoing myocardial perfusion imaging. J Nucl Cardiol 2009;16:63-72.PubMedCrossRef

Kwon DH, Cerqueira MD, young R, et al. Lessons from regadenason and low-level treadmill/regadenason myocardial perfusion imaging: Initial clinical experience in 1263 patients. J Nucl Cardiol 2010;17:853-7.PubMedCrossRef

10.

Partington SL, Lanka V, Hainer J, et al. Safety and feasibility of regadenoson use for suboptimal heart rate response during symptom-limited standard Bruce exercise stress test. J Nucl Cardiol 2012;19:970-8.

11.

Parker MW, Morales DC, Slim HB, et al. A strategy of symptom-limited exercise with regadenoson-as-needed for stress myocardial perfusion imaging: a randomized controlled trial. J Nucl Cardiol 2012. doi:10.1007/s12350-012-9641-7.

12.

Regadenoson[package insert]. Northbrook, IL: AstellasPharma US, Inc; Revised 2012 July.

13.

Wittich CM, Burkle C, Lanier WL. Ten common questions (and their answers) about off-label drug use. Mayo Clin Proc 2012;87:982-90.PubMedCrossRef

14.

Stafford PS. Regulating off-label drug use: Rethinking the role of the FDA. N Engl J Med 2008;358:1427-9.PubMedCrossRef

15.

PI Adenosine [package insert]. Northbrook, IL: AstellasPharma US, Inc; Revised 2012 July.

16.

Radley DC, Findelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med 2006;166:1021-6.PubMedCrossRef

17.

Food and Drug Administration (FDA). “Off label” and investigational use of marketed drugs, biologics, and medical devices. http://www.fda.gov/oc.ohrt/irbs/offlabel.html. Accessed 29 Sept 2012.

18.

Mello MM, Studdert DM, Brennan TA. Shifting terrain in the regulation of off-label promotion of pharmaceuticals. N Engl J Med 2009;360:1557-66.PubMedCrossRef

19.

O’Malley PG. What does off-label prescribing really mean? Arch Intern Med 2012;172:759-60.PubMedCrossRef

Title: Off-label, but on-target: Use of regadenoson with exercise
Authors: Robert C. Hendel, MD
Lauren Frost, MD
Publication date: 01-04-2013
Publisher: Springer US
Published in: Journal of Nuclear Cardiology / Issue 2/2013
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI: https://doi.org/10.1007/s12350-012-9643-5

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

At a glance: The STEP trials

Springer Medicine

Off-label, but on-target: Use of regadenoson with exercise

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2013

A strategy of symptom-limited exercise with regadenoson-as-needed for stress myocardial perfusion imaging: A randomized controlled trial

Which is the optimal acquisition time for FDG PET/CT imaging in patients with infective endocarditis?

Safety and feasibility of adjunctive regadenoson injection at peak exercise during exercise myocardial perfusion imaging: The Both Exercise and Regadenoson Stress Test (BERST) trial

Use of multimodality imaging to diagnose cardiac sarcoidosis as well as identify recurrence following heart transplantation

Regadenoson pharmacologic stress for myocardial perfusion imaging: A three-way comparison between regadenoson administered at peak exercise, during walk recovery, or no-exercise

Positron emission tomography in the assessment of left ventricular function in healthy rats: A comparison of four imaging methods

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page